Peptide Blends

What Is a Peptide Blend?

A peptide blend holds two peptides in one vial. Each peptide is synthesized and purified on its own. The two are then mixed and freeze-dried together. No chemical bond links them. Each one keeps its own sequence, mass and identity. BPC-157 is a 15-residue peptide, GEPPPGKPADDAGLV, CAS 137525-51-0 [R1]. TB-500 is Ac-LKKTETQ, a seven-residue fragment of thymosin β4 (residues 17–23) [R2]. CJC-1295 (no DAC) is GRF(1–29) amide with four substitutions: D-Ala2, Gln8, Ala15 and Leu27 [R3]. Ipamorelin is Aib-His-D-2-Nal-D-Phe-Lys-NH2 [R4][R5].

Peptide Blends Compared

Why Blends Need a Per-Component COA

A single purity number is not enough for a blend. The COA must show data for each peptide. HPLC should resolve two separate peaks, one per component. Each peak should be identified and integrated. Mass spectrometry should show both expected masses. For the BPC-157 and TB-500 blend, that means signals consistent with about 1419.5 Da and 889.0 Da. For the CJC-1295 (no DAC) and ipamorelin blend, it means a GRF(1–29) analogue mass and about 711.85 Da for ipamorelin. If only one mass appears, one component is unconfirmed. Check that the batch number on the COA matches the vial. For a step-by-step guide, read how to read a peptide COA.

Limits of the Evidence

Almost all published research studies these peptides one at a time. Findings on a single peptide do not transfer to a blend. We found one peer-reviewed study that tested BPC-157 and TB-500 together. It was an exploratory rat study of Achilles tendon tissue with four groups of eight animals. The authors reported that the combined group showed no additional benefit compared with either peptide alone [R6]. They called their findings hypothesis-generating. They also listed limits, such as one time point and small histology subsets. We did not find a peer-reviewed study that tested CJC-1295 (no DAC) and ipamorelin together. The Jetté study tested the DAC-linked form of CJC-1295, not the no-DAC peptide on its own [R3].

Regulatory Status

None of the peptides on this page is an FDA-approved drug. In a May 2026 briefing document, FDA stated that TB-500 is not a component of an FDA-approved drug. The same document states that thymosin beta-4 and TB-500 are not the same substance [R2]. A blend of two unapproved peptides is also unapproved. These products are sold for in vitro and laboratory research only. Learn more in RUO peptides explained.

Frequently Asked Questions

Is a peptide blend a new compound?

No. A blend is a physical mixture of two separately made peptides. No bond joins them. Each keeps its own sequence and mass.

How can I confirm both peptides are in the vial?

Check the batch COA. HPLC should show two resolved peaks. Mass spectrometry should show the expected mass of each peptide.

Has the BPC-157 and TB-500 combination been studied?

One exploratory rat study tested it in 2026. The combined group did not outperform either peptide alone [R6]. We found no peer-reviewed study of the CJC-1295 (no DAC) and ipamorelin pairing.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a seven-residue fragment. FDA states the two are not the same substance [R2].

References

1. U.S. Food and Drug Administration, Global Substance Registration System. BPC-157, UNII 8ED8NXK95P. precision.fda.gov
2. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23–24, 2026: Evaluation of TB-500-related bulk drug substances for inclusion on the 503A Bulk Drug Substances List. May 15, 2026. fda.gov/media/193349/download
3. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PMID 15817669.
4. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID 9849822.
5. U.S. Food and Drug Administration, Global Substance Registration System. Ipamorelin, UNII Y9M3S784Z6. precision.fda.gov
6. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. doi:10.52312/jdrs.2026.2951. PMID not yet listed.

For laboratory research use only. Not for human or veterinary use.